The 2003 Remedia Soy Formula Thiamine-Deficiency Outbreak (Israel)

In October and November of 2003, paediatric intensive-care units across Israel began admitting previously healthy infants with an unfamiliar pattern of acute heart failure, hypotonia, aphonia, and ophthalmoplegia. Three died. Within weeks, alert clinicians at Schneider Children's Medical Center of Israel in Petach Tikva — led by paediatric neurologist Aviva Fattal-Valevski and colleagues — connected the cases to a single common exposure: a soy-based infant formula sold under the Remedia Super Soya 1 brand. Analytical testing showed the product contained essentially no thiamine. A nationwide recall was issued on November 6, 2003. The Remedia outbreak remains the largest and best-documented modern incident of formula-induced infantile thiamine deficiency, and it permanently changed how infant formula is regulated worldwide. Long-term follow-up of the surviving cohort has shown that even children clinically "recovered" from acute thiamine deficiency frequently carry lifelong neurodevelopmental sequelae — particularly expressive language impairment, refractory epilepsy, motor deficits, and visual abnormalities.

The Product and the Company
The Manufacturing Error
Timeline of the Outbreak
Clinical Recognition
Three Clinical Presentations
The Three Deaths
Regulatory and Public-Health Response
Legal Aftermath
Long-Term Follow-Up of Survivors
Global Impact on Infant Formula Regulation
Lessons for Clinicians
Research Papers and References
Connections
Featured Videos

1. The Product and the Company

Remedia was at the time the second-largest infant-formula distributor in Israel. The company did not manufacture its own product; it commissioned a German company, Humana GmbH (based in Herford, North Rhine-Westphalia), to manufacture formula under the Remedia label.

Remedia Super Soya 1 was marketed for infants with cow's-milk protein allergy or lactose intolerance, and as a kosher option for observant Jewish families seeking a parve (non-dairy) formula.
Distribution share. Estimates at the time of recall suggested that roughly 5–10% of Israeli infants were being fed Remedia Super Soya 1 at some point in their first year, including most infants on a soy formula in the country.
Brand reputation. Remedia had been on the Israeli market for years and was trusted by paediatricians and parents alike; the soy variant in particular was widely prescribed for cow's-milk allergy.
Manufacturing geography. The fact that the offending product was made in Germany, distributed by an Israeli company, and consumed by Israeli infants spread regulatory responsibility across two countries' food-safety systems — a structural problem that recurs in every modern infant-formula incident.

2. The Manufacturing Error

Humana had recently reformulated the vitamin and mineral premix used in the Remedia Super Soya 1 product. The reformulation reduced the thiamine content of the premix to a level so low that the finished formula contained essentially no detectable thiamine. The error was a single-point failure in the vitamin premix specification, compounded by inadequate end-product analytical testing.

Specified content. Regulatory minimums at the time required at least 40 μg thiamine per 100 kcal of formula (the European standard then in force); the Codex Alimentarius standard is similar. A normal soy infant formula contains in the range of 60–100 μg thiamine per 100 kcal.
Measured content. Subsequent batch testing of recalled product found thiamine at less than 1 μg per 100 kcal — effectively zero relative to an infant's daily requirement.
Why end-product testing failed. The manufacturer relied on the vitamin-premix specification rather than independently assaying thiamine in the finished, retort-sterilised product. This is exactly the failure mode the Codex now requires manufacturers to guard against with mandatory finished-product analytical confirmation of each labelled vitamin.
Why no early alert from infant intake. Infants consume between 600 and 800 mL of formula per day in the first six months. A soy formula at near-zero thiamine and used as a sole feed produces no warning sign until total-body thiamine stores deplete — a process taking days to several weeks depending on the infant's birth reserves and growth rate.

3. Timeline of the Outbreak

Mid-2003. Humana introduces the reformulated vitamin premix into Remedia Super Soya 1 production batches.
October 2003. Schneider Children's Medical Center begins seeing infants with acute, unexplained cardiomyopathy and unusual neurological signs (aphonia, ophthalmoplegia, encephalopathy).
Late October–early November 2003. Aviva Fattal-Valevski and the Schneider neurology team recognise a clinical pattern. Detailed feeding histories reveal that every infant was being fed Remedia Super Soya 1, often as the exclusive feed. Empirical IV thiamine produces dramatic clinical responses in surviving cases.
November 6, 2003. The Israeli Ministry of Health announces a nationwide recall of Remedia Super Soya 1. Public-health authorities urge any family with an infant on the formula to switch immediately and to bring the infant for evaluation, regardless of apparent health.
November 2003. Active case-finding identifies approximately twenty infants with confirmed thiamine deficiency and a larger cohort with possible exposure. Three deaths attributable to thiamine-deficient cardiomyopathy are confirmed.
2004–2005. The first peer-reviewed reports appear, anchored by Fattal-Valevski's series in Pediatrics and Kornreich's neuroradiology paper in AJNR.
2005–present. Long-term follow-up of survivors continues, with major reports in 2009 (epilepsy and language), 2014 (long-term follow-up cohort), and subsequent updates.

4. Clinical Recognition

The recognition of the Remedia outbreak is a model of pattern-recognition clinical epidemiology. None of the individual cases would have raised the alarm on its own — each looked like a sporadic case of unexplained cardiomyopathy or encephalopathy. The signal came from clustering at a single hospital and from one clinical team's willingness to entertain a common nutritional cause.

The aphonic infant. Several admitted infants had been brought in for "lost voice" or "silent cry" weeks before more serious symptoms. In hindsight, aphonia was the earliest and most specific sign of evolving thiamine deficiency in the cohort.
The cross-eyed infant. Multiple parents reported the new appearance of esotropia (cross-eyes) in their previously normally aligned infants. Abducens (CN VI) palsy in an otherwise well infant is rare; its appearance in clusters was a major clue.
Lactic acidosis without sepsis. The cardiac-form infants presented with severe lactic acidosis, often >10 mmol/L, in the absence of obvious infection or hypoperfusion. Refractory lactic acidosis in an infant should always prompt the question: thiamine deficiency?
Common feeding history. Once two or three cases were linked, the feeding history of Remedia Super Soya 1 was conspicuous and led directly to the analytical investigation of the product itself.

5. Three Clinical Presentations

Fattal-Valevski's 2005 Pediatrics series of 20 infants categorised the affected cohort into three overlapping clinical syndromes, mirroring the classical descriptions of beriberi and Wernicke encephalopathy but with infant-specific features.

Cardiac form (Shoshin beriberi). Acute, often fulminant cardiomyopathy with high-output heart failure, severe lactic acidosis, cyanosis, and tachypnoea. All three deaths were in this group. Surviving cardiac-form infants typically responded dramatically to IV thiamine, with echocardiographic recovery within days.
Neurological / aphonic form. Subacute onset over days to weeks. Earliest sign was aphonia — a silent, hoarse, or weak cry. Hypotonia, poor feeding, vomiting, and lethargy followed. Without thiamine, this form progressed toward the encephalopathic picture; with thiamine, the recovery trajectory was slower than for the cardiac form but generally good in the short term.
Encephalopathic / Wernicke form. Bilateral CN VI palsy with esotropia, horizontal and rotary nystagmus, reduced consciousness, seizures, and in severe cases coma. MRI findings of bilateral symmetric basal ganglia, periaqueductal grey, and frontal white matter lesions were characteristic and helped confirm the diagnosis on admission for several patients.

6. The Three Deaths

Three Israeli infants died as a direct consequence of Remedia Super Soya 1. All three deaths were from acute thiamine-deficient cardiomyopathy (Shoshin beriberi). Their ages ranged from about three to seven months. Several additional infants survived initial cardiac arrest with cardiopulmonary resuscitation and progressed to long-term neurodevelopmental sequelae attributable to anoxic and metabolic brain injury combined with primary thiamine deficiency.

Hyperacute trajectory. In two of the three fatal cases, the interval from first clear symptom to death was less than 24 hours. The cardiac form of infantile thiamine deficiency, when missed, is a true paediatric emergency on the timescale of hours.
Misclassification risk. Without the alert from Schneider Children's, additional cardiac-form deaths could plausibly have been ascribed to viral myocarditis, sudden infant death, or undiagnosed metabolic disease. Pattern recognition saved lives.
The lasting moral weight. The deaths and the permanent sequelae in surviving children turned the Remedia case from a regulatory failure into a national trauma. Annual commemorations and the long-term cohort follow-up have kept the case in Israeli paediatric consciousness for over two decades.

7. Regulatory and Public-Health Response

Recall. The Israeli Ministry of Health issued an immediate nationwide recall of Remedia Super Soya 1 on November 6, 2003. Pharmacies and supermarkets pulled stock within hours; families were urged to return unused product.
Active case-finding. Health Ministry staff working with paediatricians traced infants exposed to the product through pharmacy purchase records and physician registries.
Empirical thiamine for exposed infants. All exposed infants, regardless of symptoms, were offered empirical thiamine supplementation and clinical assessment.
Hotline and clinic capacity. A national clinical hotline coordinated questions from worried families. Tertiary paediatric centres expanded outpatient capacity to triage exposed infants.
Regulatory reform. Israel updated its infant-formula regulations to require end-product analytical testing of every labelled micronutrient on every production batch and stricter manufacturer-of-record accountability for products distributed under a national brand.
Codex review. The Codex Alimentarius Commission and the European Food Safety Authority both reviewed infant-formula composition standards in the years following Remedia, contributing to tightened global rules on micronutrient verification.

8. Legal Aftermath

Criminal proceedings in Israel. Executives of the Remedia distribution company were prosecuted on charges related to negligence causing death. The proceedings continued for years and ended with convictions and suspended sentences for senior managers, alongside corporate fines.
Civil settlements. The affected families pursued civil claims against both Remedia and Humana. Multiple settlements over the following decade compensated families of the deceased and of survivors with permanent neurological sequelae.
Insurance and indemnification. The reinsurance market took note: infant-formula product-liability cover was repriced industry-wide after Remedia, reflecting the catastrophic potential of a single specification error.
Manufacturer–distributor liability. The case clarified, in both Israeli and European jurisprudence, that an importing distributor cannot fully delegate analytical-verification responsibility to the original manufacturer.

9. Long-Term Follow-Up of Survivors

The Remedia cohort has been followed by Fattal-Valevski and colleagues for more than a decade, producing the largest single body of evidence on the long-term neurodevelopmental consequences of acute infantile thiamine deficiency. The findings are sobering: even infants who appeared to recover completely in the acute phase have shown persistent and often progressive deficits as they aged into school years.

Language impairment. The single most consistent finding. Expressive language is more affected than receptive; some survivors with normal non-verbal IQ have isolated expressive language disorders requiring lifelong speech therapy.
Epilepsy. Approximately one-quarter of long-term follow-up patients developed epilepsy, often focal, often refractory to first-line antiepileptics, and often emerging years after the acute event.
Motor deficits. Ranging from subtle fine-motor and coordination problems to spastic diplegia and quadriplegia in the most severely affected.
Visual deficits. Persistent strabismus and optic atrophy in a meaningful subset of survivors. Several required surgical correction of esotropia.
Autistic-like features. Reported in several survivors, plausibly reflecting early thalamic, basal ganglia, and frontal white matter injury.
Cognitive variability. The cohort shows striking heterogeneity. The most important predictor of long-term outcome is the speed with which thiamine was given after symptom onset.

10. Global Impact on Infant Formula Regulation

End-product testing now standard. Post-Remedia, the European and Codex frameworks require analytical confirmation of each labelled micronutrient in finished product, not merely in the input premix. The U.S. FDA's Infant Formula Act enforcement was also strengthened.
Mandatory adverse-event reporting. The infant-formula industry now operates under mandatory adverse-event surveillance similar to that of pharmaceuticals in most developed regulatory jurisdictions.
Multi-country supply-chain accountability. Regulators now insist on chain-of-custody transparency between original manufacturer, distributor, and retailer for any formula sold under a national brand.
Clinician awareness. The Remedia case is on the syllabus for paediatric and emergency-medicine training globally. The image of an infant with new esotropia and aphonia now triggers the question: thiamine?
Recurrence elsewhere. Smaller-scale formula-related thiamine incidents have been reported subsequently in Australia (2007) and other countries; the Remedia template for rapid recognition, recall, and follow-up has shaped each response.

11. Lessons for Clinicians

Treat empirically. Any infant with unexplained acute cardiomyopathy, lactic acidosis, aphonia, new strabismus, or encephalopathy should receive IV or IM thiamine 50–100 mg before diagnostic confirmation. The risk of a dose of parenteral thiamine is negligible; the cost of delay can be death or permanent injury.
Never give glucose first. Glucose loading in a thiamine-deficient infant accelerates the metabolic crisis. Always give thiamine before, or at the same time as, any carbohydrate-rich infusion.
Ask about the formula brand and batch. Feeding history should include not only the type of formula but the brand and, if possible, batch / lot number. This becomes critical evidence in any cluster investigation.
Cluster awareness. Two or three unusual paediatric presentations in a short time window from the same catchment area warrant a phone call to the local health department. The Remedia case was solved because clinicians compared notes.
Long-term follow-up matters. Acute clinical recovery from thiamine deficiency does not equal full neurodevelopmental recovery. Surviving infants need structured follow-up through school age for language, motor, visual, and cognitive outcomes.

12. Research Papers and References

Fattal-Valevski A, Kesler A, Sela BA, Nitzan-Kaluski D, Rotstein M, Mesterman R, Toledano-Alhadef H, Stolovitch C, Hoffmann C, Globus O, Eshel G. Outbreak of life-threatening thiamine deficiency in infants in Israel caused by a defective soy-based formula. Pediatrics. 2005;115(2):e233–e238. PMID: 15687431.
Kornreich L, Bron-Harlev E, Hoffmann C, Schwarz M, Konen O, Schoenfeld T, Straussberg R, Nahum E, Ibrahim AK, Eshel G, Horev G. Thiamine deficiency in infants: MR findings in the brain. AJNR Am J Neuroradiol. 2005;26(7):1668–1674. PMID: 16091511.
Fattal-Valevski A, Azouri-Fattal I, Greenstein YJ, Guindy M, Blau A, Zelnik N. Delayed language development due to infantile thiamine deficiency. Dev Med Child Neurol. 2009;51(8):629–634. PMID: 19416328.
Fattal-Valevski A, Bloch-Mimouni A, Kivity S, Heyman E, Brezner A, Strausberg R, Inbar D, Kramer U, Goldberg-Stern H. Epilepsy in children with infantile thiamine deficiency. Neurology. 2009;73(11):828–833. PMID: 19571253.
Mimouni-Bloch A, Goldberg-Stern H, Strausberg R, Brezner A, Heyman E, Inbar D, Kivity S, Zvulunov A, Sztarkier I, Fogelman R, Fattal-Valevski A. Thiamine deficiency in infancy: long-term follow-up. Pediatr Neurol. 2014;51(3):311–316. PMID: 25160535.
Fattal-Valevski A, Greenstein Y, Bloch-Mimouni A, Tziperman B, Heyman E, Brezner A, Kramer U. Hypertonia as a clinical manifestation of infantile thiamine deficiency. J Child Neurol. 2013;28(11):1413–1417. PMID: 23271754.
Harel Y, Zuk L, Guindy M, Nakar O, Lotan D, Fattal-Valevski A. The effect of subclinical infantile thiamine deficiency on motor function in preschool children. Matern Child Nutr. 2017;13(4):e12054. PMID: 26790557.
Zelnik N, Pacht A, Obeid R, Lerner A. Range of neurologic disorders in patients with celiac disease. Pediatrics. 2004;113(6):1672–1676. PMID: 15173490.
Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442–455. PMID: 17434099.
Vasconcelos MM, Silva KP, Vidal G, Silva AF, Domingues RC, Berditchevsky CR. Early diagnosis of pediatric Wernicke's encephalopathy. Pediatr Neurol. 1999;20(4):289–294. PMID: 10328280.
Whitfield KC, Bourassa MW, Adamolekun B, Bergeron G, Bettendorff L, Brown KH, Cox L, Fattal-Valevski A, Fischer PR, Frank EL, Hiffler L, Hlaing LM, Jefferds ME, Kapner H, Kounnavong S, Mousavi MPS, Roth DE, Tsaloglou MN, Wieringa F, Combs GF Jr. Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs. Ann N Y Acad Sci. 2018;1430(1):3–43. PMID: 30151974.
Ortigoza-Escobar JD, Pérez-Dueñas B. Genetic defects of thiamine transport and metabolism. Pediatr Neurol. 2018;87:5–14. PMID: 30343745.

Live PubMed Searches

Back to Table of Contents

Connections

Back to Table of Contents

Featured Videos

Medicosis Perfectionalis — Infantile Beriberi - Vitamin B1 Deficiency - Thiamine Deficiency

JJ Medicine — Beriberi (Thiamine Deficiency): Wet vs Dry Beriberi, Pathophysiology, Symptoms, Diagnosis, Treatment

Medsimplified AI — 8. Thiamine (Vitamin B1) | Functions, Beriberi, Wernicke–Korsakoff Syndrome MBBS Biochemistry USMLE

Medicine in 3 minutes — 3-Minute: Vit B1 Deficiency/ Thiamine/ Beriberi/ Wernicke-Korsakoff Alcoholism/

Dr.X — Thiamine (Vitamin B1) Explained: Beriberi, Wernicke-Korsakoff, PDC, and Exam Pearls

Biochemistry by Dr Rajesh Jambhulkar — Thiamine - Beri-beri and Wernicke- Korsakoff syndrome

Dr Vijaya Marakala — Vitamin B1: Thiamine: Water soluble vitamins: Biochemistry

GAGANA DEEPA — Vitamin B1 (Thiamine) in 5 MINUTES

AETCM Emergency Medicine — BeriBeri || Thiamine deficiency

Dr. Dipendra Kandel — Various manifestations of Vitamin B1 deficiency| USMLE step 1 | Lecture 4.1

Dr. Ashish Anjankar — Beriberi (Vitamin B1 Deficiency) - Case in Vitamins

Biochemistry by Dr.Arindam Ghosh — Thiamine (Vitamin B1) Must know areas to study before examination.

Medical-Question — Beriberi in thiamine deficiency (vitamin B1) How does dry beriberi different from wet beriberi?

ETV Andhra Pradesh — Cardiac Beri Beri with vitamin B1 Deficiency | Sukhibhava | 16th August 2021 | ETV Andhra Pradesh

PETROMed Lectures — Vitamin B1 (Thiamine) - Biochemistry Video for Medical Students - USMLE Step 1

Health Education — 14 weird sign of vitamin B1 deficiency and Benefits.